American Heart Journal
Volume 144, Issue 6 , Pages 933-937 , December 2002

Things ain't what they used to be: Impact of a new definition of myocardial infarction

References 

  1. The Joint European Society of Cardiology/American College of Cardiology Committee . Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol. 2000;36:959–969
  2. Dargie H. Myocardial infarction: redefined or reinvented? [editorial]. Heart. 2002;88:1–3
  3. Birkhead JS. Defining myocardial infarction: not too late for common sense or consistency?. Hospital Medicine. 2001;62:260–261
  4. Richards AM, Lainchbury JG, Nicholls MG. Unsatisfactory redefinition of myocardial infarction ]commentary[. Lancet. 2001;357:1635–1636
  5. Tormey W. Redefinition of myocardial infarction [letter]. Lancet. 2001;358:764
  6. Tunstall-Pedoe H. Comment on the ESC/ACC redefinition of myocardial infarction by a consensus dissenter [letter]. Eur Heart J. 2001;22:613–615
  7. WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583–612
  8. Newby LK, Alpert JS, Ohman EM, et al.  Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. Am Heart J. 2002;144:957–980
  9. Apple FS, Wu AHB, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J. 2002;144:981–986
  10. Venge P, Lindahl B, Wallentin L. New generation cardiac troponin I assay for the access immunoassay system. Clin Chem. 2001;47:959–961
  11. Braunwald E, Antman EM, Beasley JW, et al.  ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation. 2000;102:1193–1209
  12. Wu AH, Apple FS, Gibler WB, et al.  National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem. 1999;45:1104–1121
  13. Pell ACH, Pell JP. Was it a heart attack? variations in access to and interpretation of troponin assays are wide [letter]. Br Med J. 2002;324:1216
  14. Pfeffer MA, McMurray JJ. Myocardial infarct: no one size fits all. Circulation. 2002;105:2577–2579
  15. Califf RM, Abdelmeguid AE, Kuntz RE, et al.  Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241–251
  16. Costa MA, Carere RG, Lichtenstein SV, et al.  Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the Arterial Revascularization Therapies Study (ARTS). Circulation. 2001;104:2689–2693
  17. Ottani F, Galvani M, Nicolini FA, et al.  Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000;140:917–927
  18. Cantor WJ, Newby LK, Christenson RH, et al.  Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol. 2002;39:1738–1744
  19. Wu AH, Boden WE, McKay RG. Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. Am J Cardiol. 2002;89:1300–1302
  20. Brener SJ, Ellis SG, Schneider J, et al.  Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J. 2002;23:869–876
  21. Januzzi JL, Lewandrowski K, MacGillivray TE, et al.  A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll Cardiol. 2002;39:1518–1523
  22. Lee ME, Sethna DH, Conklin CM, et al.  CK-MB release following coronary artery bypass grafting in the absence of myocardial infarction. Ann Thorac Surg. 1983;35:277–279
  23. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol. 1997;29:43–48
  24. Heeschen C, Hamm CW, Goldmann B, et al.  Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999;354:1757–1762
  25. Morrow DA, Antman EM, Tanasijevic M, et al.  Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000;36:1812–1817
  26. Antman EM. Troponin measurements in ischemic heart disease: more than just a black and white picture [editorial]. J Am Coll Cardiol. 2001;38:987–990
  27. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease (FRISC II) Investigators . Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II Prospective Randomised Multicentre Study. Lancet. 1999;354:708–715
  28. Cannon CP, Weintraub WS, Demopoulos LA, et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887

☆ Reprint requests: Harvey White, DSc, Cardiology Department, Green Lane Hospital, Private Bag 92-189, Auckland 1030, New Zealand.

☆☆ E-mail: harveyw@adhb.govt.nz

PII: S0002-8703(02)00216-8

doi: 10.1067/mhj.2002.129780

American Heart Journal
Volume 144, Issue 6 , Pages 933-937 , December 2002

Article Tools

* Image Usage & Resolution